<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">20485552</PMID>
        <DateCompleted>
            <Year>2010</Year>
            <Month>09</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>5</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>May</Month>
                        <Day>12</Day>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS One</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Development of and access to products for neglected diseases.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e10610</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0010610</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Prior research on neglected disease drug development suggested inadequate funding was responsible for relatively few new approvals. In response, significantly more resources have been allocated towards development of drugs targeting neglected diseases. Our objective was to reassess drug development between 1975 and 1999, evaluate progress in neglected disease drug development since 2000, and explain how increased numbers of approvals are a necessary but insufficient condition to improving access.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">To assess numbers of approvals targeting neglected diseases, we employed two distinct methodologies: First, to revisit numbers published in Trouiller et al. (2002) we used their method to count marketed new chemical entities (NCEs) between 1975 and 1999. Second, using the G-Finder report as a benchmark, we identified which diseases are currently considered &quot;neglected&quot; to tally approvals in the 1975-1999 and 2000-2009 periods. Searching PharmaProjects and IMS R&amp;D Focus databases as well as websites from numerous drug regulatory agencies, we identified new drug approvals and indications. Also, we examined the World Health Organization's (WHO) Essential Drug List (EDL) to see which drugs and indications were on the list.</AbstractText>
                <AbstractText Label="FINDINGS" NlmCategory="RESULTS">Upon recount, using Trouiller et al. methodology, we found that between 1975 and 1999 more NCEs (n = 32) targeting tropical diseases and tuberculosis were approved than reported in Trouiller et al. (n = 16). Using the G-Finder method of defining neglected diseases, we found 46 new drug approvals between 1975 and 1999. WHO included 85% of these drugs on the EDL. In the period 2000 to May 2009, despite much greater funding, only 26 new drugs and vaccines for neglected diseases were marketed. Of these, WHO placed 50% on the EDL.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Product approvals for neglected diseases have increased, though progress has been uneven, with malaria appearing to benefit most in the short run from increased funding, while less success has been booked in other disease categories. Uneven progress suggests funding could be better targeted, particularly with regard to neglected diseases that have hitherto received scant attention. In addition, policymakers should focus on other aspects related to access. Besides drug development, there are the issues of EDL listing, architecture, availability, affordability, and adoption.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cohen</LastName>
                    <ForeName>Joshua</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tufts University Center for the Study of Drug Development, Boston, Massachusetts, United States of America. joshua.cohen@tufts.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dibner</LastName>
                    <ForeName>Maria Staroselsky</ForeName>
                    <Initials>MS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wilson</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>05</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D004194" MajorTopicYN="Y">Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006297" MajorTopicYN="Y">Health Services Accessibility</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2010</Year>
                <Month>01</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2010</Year>
                <Month>04</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>5</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>5</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>9</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20485552</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0010610</ArticleId>
            <ArticleId IdType="pmc">PMC2868904</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Trop Med Int Health. 2001 Nov;6(11):945-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11703850</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2002 Jun 22;359(9324):2188-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12090998</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2003 Nov;2(11):919-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14668812</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Med. 2005 Sep;2(9):e302</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16138789</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Health Aff (Millwood). 2009 Jul-Aug;28(4):962-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19597194</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Trop Med Int Health. 2006 Sep;11(9):1335-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16930253</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Pharmacol Ther. 2007 Nov;82(5):498-500</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17952104</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Med. 2009 Feb 3;6(2):e30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19192946</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Health Aff (Millwood). 2009 May-Jun;28(3):w411-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19299425</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2006 May 13;367(9522):1560-1</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16698397</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
